SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosusV. Werth, Douglas R. Hough, Richard Furie et al.|Annals of the Rheumatic Diseases|2017Cited by 6
OP0005 NAVIGATING COMPLEXITIES OF MULTIPLE POSITIVE MYOSITIS AUTOANTIBODIES: ANALYSIS FROM CLASSIFICATION CRITERIA OF ANTI-SYNTHETASE SYNDROME (CLASS) PROJECTAravinthan Loganathan, L. Cavagna, Gianluca Sambataro et al.|Annals of the Rheumatic Diseases|2024Cited by 2
POS1281 CLINICAL CHARACTERISTICS OF ANTI-SYNTHETASE SYNDROME: ANALYSIS FROM THE CLASS PROJECTSara Faghihi‐Kashani, L. Cavagna, Akira Yoshida et al.|Annals of the Rheumatic Diseases|2024Cited by 2
379 A phase 2, randomized, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics & pharmacogenetics of CC-220 in subjects with SLEV. Werth, Seohee Choi, Richard Furie et al.|Journal of Investigative Dermatology|2017Cited by 0